Leclaza plus Rybrevant combination therapy has been listed as a first-line therapy in global guidelines after demonstrating improvements in survival rates.

Leclaza plus Rybrevant combination therapy, which is the new treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), received U.S. Food and Drug Administration (FDA) approval as a first-line therapy last month. This combination therapy showed statistically improved progression-free survival (PFS) and overall survival (OS) than Tagrisso monotherapy.

Leclaza plus Rybrevant combination therapy has been listed in the NCCN guideline…demonstrated clinical effectiveness